Sub-50 nm Gas Vesicle Nanostructures for Lymphatic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ultrasound-mediated gene delivery technologies are limited by the size of microbubbles, which restrict their biodistribution to well-vascularized regions, making it difficult to access cells outside the blood vessels, and there is a need for gas-filled agents with a hydrodynamic radius below 100 nm to optimize delivery efficiency, especially for lymphatic and neuronal targets.
Innovation Solution
Genetically engineered gas vesicle compositions with modified shell proteins, allowing for the formation of sub-50 nm gas-filled protein nanostructures that are stable, free-floating, and capable of extravasating into lymphatic tissues, enabling access to previously inaccessible cell populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If microbubbles are used for ultrasound-mediated gene delivery, then delivery to well-vascularized regions is achieved, but delivery to cells outside blood vessels and lymphatic/neuronal targets is limited due to size constraints
Solution Approach 1:
The patent applies parameter changes by modifying the physical size parameter of gas-filled agents from micrometer-scale microbubbles (1-5 μm) to nanometer-scale gas vesicles (sub-50 nm hydrodynamic radius). This size parameter change enables the agents to extravasate from blood vessels and access previously inaccessible compartments including lymphatic tissues and neuronal cells, thereby resolving the contradiction between size and biodistribution versatility
Solution Approach 2:
The patent uses genetically engineered gas vesicle shell proteins as biological templates to create ultrasmall gas-filled nanostructures. By copying and modifying natural gas vesicle proteins (gvpA, gvpB) through genetic engineering, the invention produces synthetic nanostructures that maintain the functional properties of natural gas vesicles while achieving the desired sub-50 nm size for enhanced biodistribution
2Adaptability or versatility
If genetically engineered gas vesicle compositions are used, then access to lymphatic and neuronal cells is enabled, but complexity of protein engineering increases
Solution Approach 1:
The patent applies self-service by utilizing the natural self-assembly properties of gas vesicle shell proteins. The genetically engineered gvpA and gvpB proteins automatically self-assemble into functional gas vesicle structures without requiring complex external assembly procedures. This self-assembly mechanism simplifies the manufacturing process despite the genetic engineering involved, as the proteins perform their own organization and vesicle formation functions
Solution Approach 2:
The patent achieves versatility through universal gas vesicle compositions that can be used for multiple applications including ultrasound imaging, gene delivery, and drug delivery to various tissue types (vascularized tissues, lymphatic systems, and neuronal targets). The same basic gas vesicle platform with modified shell proteins serves multiple therapeutic and diagnostic functions, reducing the need for separate engineered solutions for each application
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sub-50 nm gas vesicle compositions facilitate ultrasound-mediated delivery to lymphatic and neuronal cells, enhancing the efficacy of gene and drug delivery while allowing for tracking and imaging, thus overcoming the limitations of conventional microbubble-based technologies.
Implementation Method 1
ultrasound-mediated delivery to lymphatic and neuronal cells, enhancing the efficacy of gene and drug delivery while allowing for tracking and imaging
Data Source
AI summary
In one aspect, the present disclosure describes ultrasmall gas vesicle compositions comprising modified gas vesicle shell proteins. Also disclosed herein are polynucleotide sequences which encode such compositions. Methods of treatment comprising administering such gas vesicle compositions are also provided.